RB1 and neoplasm: These results suggest that during tumor clonal evolution, palbociclib plus ET treatment selected for tumor subclones with RB1 loss-of-function that mediated cell cycle deregulation and potentially led to elevated levels of replication stress and the subsequent induction of APOBEC-mediated mutagenesis.